535 related articles for article (PubMed ID: 27059952)
21. What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism.
; Tougher S; Hanson K; Goodman C
Malar J; 2017 Apr; 16(1):173. PubMed ID: 28441956
[TBL] [Abstract][Full Text] [Related]
22. A new approach to gathering pharmaceutical market data to support policy implementation and access to medicines: as demonstrated by malaria medicines in Zambia.
Coghlan R; Stephens P; Mwale B; Siyanga M
Malar J; 2018 Nov; 17(1):444. PubMed ID: 30497504
[TBL] [Abstract][Full Text] [Related]
23. Access to artemisinin-combination therapy (ACT) and other anti-malarials: national policy and markets in Sierra Leone.
Amuasi JH; Diap G; Nguah SB; Karikari P; Boakye I; Jambai A; Lahai WK; Louie KS; Kiechel JR
PLoS One; 2012; 7(10):e47733. PubMed ID: 23133522
[TBL] [Abstract][Full Text] [Related]
24. Social and cultural complexities of anti-malarial drug circulation: an ethnographic investigation in three rural remote communes of Cambodia.
Res P
Malar J; 2017 Oct; 16(1):428. PubMed ID: 29070076
[TBL] [Abstract][Full Text] [Related]
25. Insights into the availability and distribution of oral artemisinin monotherapy in Myanmar: evidence from a nationally representative outlet survey.
; Thein ST; Khin HSS; Thi A
Malar J; 2017 Apr; 16(1):170. PubMed ID: 28438145
[TBL] [Abstract][Full Text] [Related]
26. Determinants of price setting decisions on anti-malarial drugs at retail shops in Cambodia.
Patouillard E; Hanson K; Kleinschmidt I; Palafox B; Tougher S; Pok S; O'Connell K; Goodman C
Malar J; 2015 May; 14():224. PubMed ID: 26024880
[TBL] [Abstract][Full Text] [Related]
27. Who continues to stock oral artemisinin monotherapy? Results of a provider survey in Myanmar.
Thein ST; Sudhinaraset M; Khin HS; McFarland W; Aung T
Malar J; 2016 Jun; 15():334. PubMed ID: 27333781
[TBL] [Abstract][Full Text] [Related]
28. The impact of the private sector co-payment mechanism (PSCM) on the private market for ACT in Nigeria: results of the 2018 cross-sectional outlet and household market surveys.
Edwards HM; Sarwar R; Mahmud P; Emmanuel S; Maxwell K; Tibenderana JK
Malar J; 2022 Feb; 21(1):42. PubMed ID: 35151332
[TBL] [Abstract][Full Text] [Related]
29. Treatment-seeking patterns for malaria in pharmacies in five sub-Saharan African countries.
Ladner J; Davis B; Audureau E; Saba J
Malar J; 2017 Aug; 16(1):353. PubMed ID: 28851358
[TBL] [Abstract][Full Text] [Related]
30. Access to artesunate-amodiaquine, quinine and other anti-malarials: policy and markets in Burundi.
Amuasi JH; Diap G; Blay-Nguah S; Boakye I; Karikari PE; Dismas B; Karenzo J; Nsabiyumva L; Louie KS; Kiechel JR
Malar J; 2011 Feb; 10():34. PubMed ID: 21310057
[TBL] [Abstract][Full Text] [Related]
31. Availability and quality of anti-malarials among private sector outlets in Myanmar in 2012: results from a large, community-based, cross-sectional survey before a large-scale intervention.
Khin HS; Chen I; White C; Sudhinaraset M; McFarland W; Littrell M; Montagu D; Aung T
Malar J; 2015 Jul; 14():269. PubMed ID: 26169498
[TBL] [Abstract][Full Text] [Related]
32. Improvements in access to malaria treatment in Tanzania after switch to artemisinin combination therapy and the introduction of accredited drug dispensing outlets - a provider perspective.
Alba S; Hetzel MW; Goodman C; Dillip A; Liana J; Mshinda H; Lengeler C
Malar J; 2010 Jun; 9():164. PubMed ID: 20550654
[TBL] [Abstract][Full Text] [Related]
33. Trends in access to anti-malarial treatment in the formal private sector in Uganda: an assessment of availability and affordability of first-line anti-malarials and diagnostics between 2007 and 2018.
Kibira D; Ssebagereka A; van den Ham HA; Opigo J; Katamba H; Seru M; Reed T; Leufkens HG; Mantel-Teeuwisse AK
Malar J; 2021 Mar; 20(1):142. PubMed ID: 33691704
[TBL] [Abstract][Full Text] [Related]
34. Health service providers in Somalia: their readiness to provide malaria case-management.
Noor AM; Rage IA; Moonen B; Snow RW
Malar J; 2009 May; 8():100. PubMed ID: 19439097
[TBL] [Abstract][Full Text] [Related]
35. Provider knowledge of treatment policy and dosing regimen with artemether-lumefantrine and quinine in malaria-endemic areas of western Kenya.
Watsierah CA; Onyango RO; Ombaka JH; Abong'o BO; Ouma C
Malar J; 2012 Dec; 11():436. PubMed ID: 23273046
[TBL] [Abstract][Full Text] [Related]
36. Copayment mechanism in selected districts of Uganda: Availability, market share and price of quality assured artemisinin-based combination therapies in private drug outlets.
Ocan M; Nambatya W; Otike C; Nakalembe L; Nsobya S
PLoS One; 2024; 19(3):e0295198. PubMed ID: 38536824
[TBL] [Abstract][Full Text] [Related]
37. Methods for implementing a medicine outlet survey: lessons from the anti-malarial market.
O'Connell KA; Poyer S; Solomon T; Munroe E; Patouillard E; Njogu J; Evance I; Hanson K; Shewchuk T; Goodman C
Malar J; 2013 Feb; 12():52. PubMed ID: 23383972
[TBL] [Abstract][Full Text] [Related]
38. Anti-malarial market and policy surveys in sub-Saharan Africa.
Diap G; Amuasi J; Boakye I; Sevcsik AM; Pecoul B
Malar J; 2010 Apr; 9 Suppl 1(Suppl 3):S1. PubMed ID: 20423536
[TBL] [Abstract][Full Text] [Related]
39. Drugs use pattern for uncomplicated malaria in medicine retail outlets in Enugu urban, southeast Nigeria: implications for malaria treatment policy.
Ezenduka CC; Ogbonna BO; Ekwunife OI; Okonta MJ; Esimone CO
Malar J; 2014 Jun; 13():243. PubMed ID: 24961280
[TBL] [Abstract][Full Text] [Related]
40. Access to artemisinin-based combination therapy (ACT) and quinine in malaria holoendemic regions of western Kenya.
Watsierah CA; Ouma C
Malar J; 2014 Jul; 13():290. PubMed ID: 25066600
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
